Psyence Biomedical logo

Psyence Biomedical(NASDAQ) PBMWW

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-70%
5 YearN/A
1 Year-54%
1 Month-47%
$0.02
-35.59%
-0.01Today
Psyence Biomedical last closing stock price
MetricPriceDate
Last closeUSD 0.022026-10-13
Psyence Biomedical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-22.05%USD 0.022026-10-06
1 month-47.4%USD 0.032026-09-11
3 month-24%USD 0.022026-07-15
Year to date-18.04%USD 0.022025-12-31
1 year-53.99%USD 0.032025-10-13
Since inception-69.6%USD 0.052024-01-26

Psyence Biomedical Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$26.25M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-1.48 (Low)

Price

$0.02

Volume

134

Open

$0.02

Previous Close

$0.02

Daily Range

$0.02 - $0.02

52-Week Range

$0.01 - $0.09

Estimated Earnings Date

N/A

PBMWW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Psyence Biomedical

Psyence Biomedical Ltd. focuses on developing psychedelic medications derived from botanical psilocybin. The company is investigating the use of natural psilocybin to alleviate adjustment disorder in patients with incurable cancer undergoing palliative care.

Products and Services
  • PEX010: A capsule containing naturally sourced psilocybin
  • Clinical trials for psilocybin-assisted psychotherapy
  • Research on psilocybin's effects on anxiety and depression
Growth Outlook
  • Partnership with iNGENu Pty Ltd for Phase IIb clinical trials
  • Increasing interest in psychedelic therapies in healthcare
  • Potential market expansion as regulations evolve
Financial Highlights
  • Recent quarterly net income of -$753,254
  • Cash and cash equivalents of $7,197,176 as of September 30, 2025
  • Current ratio of 14.62 indicates strong liquidity position
Psyence Biomedical Ltd. is positioned in the biotechnology sector, focusing on innovative treatments that leverage the therapeutic potential of psilocybin. The primary product candidate, PEX010, is currently undergoing clinical trials, which could pave the way for significant advancements in mental health treatment. The partnership with iNGENu Pty Ltd enhances the company's research capabilities, potentially leading to breakthroughs in psilocybin-assisted psychotherapy. Financially, the company has demonstrated a robust liquidity position with a current ratio of 14.62, indicating a strong ability to meet short-term obligations. Despite recent net losses, the substantial cash reserves provide a buffer for ongoing research and development efforts. As the market for psychedelic therapies continues to grow, Psyence Biomedical Ltd. may benefit from evolving regulations and increasing acceptance of these innovative treatments.
AI Generated • Sep 15, 2026

Industry

Biotechnology

Headquarters

Toronto, ON M5H 2K1, CA

PBMWW Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-58.62%

Return on Capital

-36.81%

Return on Assets

-39.48%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

134

Avg. Volume

31.11K

Financials (TTM)

Gross Profit

-$2.35K

Operating Income

-$3.47M

EBITDA

-$2.11M

Operating Cash Flow

-CA$1.05M

Capital Expenditure

-CA$7.80

Free Cash Flow

-CA$1.05M

Cash & ST Invst.

$7.20M

Total Debt

$0.00

Psyence Biomedical Performance Analysis

Psyence Biomedical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-09-30N/A
Q32023-12-31N/A
Q22024-09-30N/A
Q22025-09-30N/A
Psyence Biomedical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-09-30-979.5%
Q32023-12-31-2097.1%
Q22024-09-30N/A
Q22025-09-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$1.33K

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

12

N/A

Net Income

-$753.25K

-1098.6%

EBITDA

-$749.17K

-799.9%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

$7.20M

+73325.6%

Total Debt

$0.00

-100.0%

Accounts Receivable

$174.19K

+159.3%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-39.48%

N/A

Return on Invested Capital

-36.81%

N/A

Free Cash Flow

-$665.00

+99.2%

Operating Cash Flow

-$662.00

+99.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,803.85-0.00%
^DJIDJI
$51,687.96-0.00%
^IXICNASDAQ
$27,201.84-0.00%
BTCBitcoin
$83,069.00+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$37.42+0.62%
KORUDirexion Shares ETF Trust - Direxion Daily Msci South Korea Bull 3x Shares
$14.72-6.48%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$127.57-0.65%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$33.99+1.06%

Questions About PBMWW

What is the current price of Psyence Biomedical?

Psyence Biomedical is trading at $0.02 per share.

What is the 52-week range for Psyence Biomedical?

Over the past 52 weeks, Psyence Biomedical has traded between $0.01 and $0.09.

How much debt does Psyence Biomedical have?

Psyence Biomedical total debt is unavailable.

How much cash does Psyence Biomedical have on hand?

Psyence Biomedical does not have cash on hand data available.

What is Psyence Biomedical’s dividend yield?

Psyence Biomedical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.